Search results
Author(s):
Gi-Byoung Nam
,
Min Soo Cho
Added:
1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study…
View more
Added:
4 months ago
Source:
Arrhythmia Academy
Managing antithrombotic therapy in older patients with both atrial fibrillation (AF) and stable coronary artery disease (CAD) presents a clinical challenge, balancing the risks of thrombotic events and bleeding. A new post hoc analysis of the AFIRE trial sought to clarify whether the effects of rivaroxaban monotherapy differ across age groups compared to combination therapy with an antiplatelet…
View more
Matthew Ryan
Job title: Cardiologist
Author
K Lance Gould
Job title: Martin Bucksbaum Distinguished University Chair, Professor and Director
Author
Author(s):
Sarah Ming Li Tan
,
Shir Lynn Lim
,
Marcus EH Ong
,
et al
Added:
5 months ago
Clint Maart
Job title: Consultant Interventional Cardiologist
Author
William E Boden
Job title: Professor of Medicine
Author
Tomohiro Sakamoto
Job title: Interventional Cardiologist
Author
Prof José C Nicolau
Job title: Professor Nicolau’s main area of research includes the broad spectrum of coronary artery disease (mainly ACS)
Author
Author(s):
Meng-Chang Lee
,
Chun-Wei Lu
,
Mei-Hwan Wu
Added:
1 month ago